

Table of Contents

Acknowledgements	i
Table of contents	iv
List of abbreviations	vi
1. General Introduction	1
1.1 High Grade Glioma: an unmet medical need	1
1.1.1 Classification	1
1.1.2 Genomic background	1
1.1.3 Diagnosis and Standard of Care	2
1.2 Cancer immunology	3
1.2.1 Immune surveillance	3
1.2.2 Immune contexture for GBM: a battlefield between activation and suppression	4
1.2.2.1 Immune activation	4
1.2.2.2 Immune Suppression	5
1.2.2.3 Tumor derived factors for immune suppression	6
1.2.2.4 Immunotherapy	6
1.3 Galectin-1	7
1.3.1 Galectin-1 as a natural immune suppressive lectin	7
1.3.2 Non-immunological features of Gal-1 that drive tumor progression.	9
1.4 Local Administrations to treat GBM	11
1.5 Intranasal administration	12
1.5.1 Anatomy relevant for nose-to-brain transport	12
1.5.2 Macroscopical anatomy	12
1.5.2.1 Olfactory pathway/olfactory region	13
1.5.2.2 Trigeminal pathway/respiratory region	13
1.5.2.3 Other possible pathways	13
1.5.3 Microscopical anatomy	14

1.5.3.1 Nasal mucosa and mucus	14
1.5.3.2 Paracellular transport between nasal mucosa	15
1.5.3.3 Transcellular transport across nasal mucosa	15
1.5.3.4 Organization nerves/filia olfactoria	15
1.6 Pre-clinical and clinical evidence of nose-to-brain transport for GBM	16
1.6.1 Intranasal administration for GBM	16
1.6.1.1 Animal models	16
1.6.1.2 Clinical setting	18
1.6.1.3 Possible pitfalls	19
1.7 Improvement of the nose-to-brain pathway through formulations	20
1.7.1 Via Polymer-based nanoparticles	20
1.7.2 Lipid based nanosized formulations	23
1.7.2.1 Via (nano)emulsions	23
1.7.2.2 Via solid lipid nanoparticles	23
1.7.2.3 Via liposomes	23
1.7.3 Functionalization of the nanoparticle surface by ligands	24
1.7.4 Via gels	25
1.7.5 Via Indirect enhancers / devices	25
2. Aims and Objectives	27
3. RESULTS – PART 1: Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration	29
4. RESULTS – PART2: Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy	53
5. RESULTS - PART 3: PEGylated chitosan nanoparticles optimize nose-to-brain transport to target Galectin-1 in the treatment of glioblastoma	73
6. Addendum – Carrier development	83

7. Final discussion and Perspectives	95
Abstract	101
Summary	103
Samenvatting	105
References	107
Curriculum vitae	123
Bibliography and awards	125
Posters and presentations	127